센티 바이오사이언시스SNTI 주가

♻️ 재탕[8-K] 중대 사건 — 8-K

Chardan Capital Maintains Buy on Senti Biosciences, Raises Price Target to $12

Chardan Capital analyst Geulah Livshits maintains Senti Biosciences (NASDAQ:SNTI) with a Buy and raises the price target from $11 to $12.

Senti Biosciences Holdings announces positive FDA RMAT meeting on registrational clinical and CMC strategy

Senti Biosciences Holdings Inc:Senti Biosciences Holdings announces positive FDA RMAT meeting on registrational clinical and CMC strategy for SENTI-202 in relapsed/refractory acute myeloid leukemia,...

Senti Biosciences Q1 EPS $(0.14) Beats $(0.36) Estimate, Sales $16.000K

Senti Biosciences (NASDAQ:SNTI) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.36) by 61.11 percent. This is a 90.07 percent increase over losses of $(1.41) per share from

Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase

Secured strategic financing vehicle for up to $40 million Positive FDA feedback supports single-arm pivotal trial for potential registration of SENTI-202 in initial indication of Relapsed/Refractory...

Senti Biosciences Announces Completion Of Type B Initial Comprehensive Multidisciplinary RMAT Meeting With FDA Regarding SENTI-202, Logic Gated Off-The-Shelf CAR-NK Cell Therapy For R/R AML And Updated Phase 1 Clinical Data

Following a Type B meeting with FDA, Senti Bio plans to proceed with a single-arm multi-center registrational trial for SENTI-202, building off the strong Phase 1 clinical results demonstrating deep and durable

Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program

Following a Type B meeting with FDA, Senti Bio plans to proceed with a single-arm multi-center registrational trial for SENTI-202, building off the strong Phase 1 clinical results demonstrating deep...

[10-Q] 분기 실적 — 10-Q

[8-K] 중대 사건 — 8-K

[15-12G] 15-12G — 15-12G